FDA warns Proc­ter & Gam­ble over NyQuil la­bel's in­gre­di­ent list­ings

The FDA on Tues­day re­leased a warn­ing let­ter sent ear­li­er this month to the Ma­son, OH-based site of Proc­ter & Gam­ble Man­u­fac­tura, rais­ing ques­tions about the list of in­gre­di­ents on the la­bel and in the elec­tron­ic fil­ing.

The warn­ing says that for P&G’s over-the-counter Vicks Nyquil Se­vere Hot Rem­e­dy Cold and Flu Plus Con­ges­tion, there’s a “mis­matched” list of ac­tive in­gre­di­ents be­tween the la­bel­ing and the elec­tron­ic list­ing file. The list­ing file for the ac­tive in­gre­di­ents did not match the ac­tive in­gre­di­ents in the elec­tron­ic file.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN